Court Grants Permanent Injunction For Infringement Of Amgen's Repatha Patents
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Amgen (AMGN) PT Raised to $165 at Baird on Permanent Injunction Win
January 6, 2017 6:16 AM ESTBaird analyst Brian Skorney raised his price target on Amgen (NASDAQ: AMGN) to $165.00 (from $157.00), saying they are incrementally positive on permanent injunction win. The firm maintained a Neutral rating.
Skorney commented, "Amgen continues to rack up wins against Regeneron and Sanofi, with the most... More
